title: Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantation.
authors.affiliation: Division of Hematology/Oncology, Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA.
authors.forename: J A
authors.initials: JA
authors.lastname: Yared
authors.affiliation: Division of Hematology/Oncology, Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA.
authors.forename: N
authors.initials: N
authors.lastname: Hardy
authors.affiliation: Department of Pathology, University of Maryland, Baltimore, MD, USA.
authors.forename: Z
authors.initials: Z
authors.lastname: Singh
authors.affiliation: Department of Diagnostic Radiology and Nuclear Medicine, University of Maryland, Baltimore, MD, USA.
authors.forename: S
authors.initials: S
authors.lastname: Hajj
authors.affiliation: Division of Hematology/Oncology, Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA.
authors.forename: A Z
authors.initials: AZ
authors.lastname: Badros
authors.affiliation: Division of Hematology/Oncology, Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA.
authors.forename: M
authors.initials: M
authors.lastname: Kocoglu
authors.affiliation: Division of Hematology/Oncology, Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA.
authors.forename: S
authors.initials: S
authors.lastname: Yanovich
authors.affiliation: Division of Hematology/Oncology, Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA.
authors.forename: E A
authors.initials: EA
authors.lastname: Sausville
authors.affiliation: Division of Hematology/Oncology, Lombardi Cancer Center, Georgetown University, Washington DC, WA, USA.
authors.forename: C
authors.initials: C
authors.lastname: Ujjani
authors.affiliation: Division of Hematology/Oncology, Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA.
authors.forename: K
authors.initials: K
authors.lastname: Ruehle
authors.affiliation: Division of Hematology/Oncology, Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA.
authors.forename: C
authors.initials: C
authors.lastname: Goecke
authors.affiliation: Division of Hematology/Oncology, Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA.
authors.forename: M
authors.initials: M
authors.lastname: Landau
authors.affiliation: Division of Hematology/Oncology, Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA.
authors.forename: A P
authors.initials: AP
authors.lastname: Rapoport
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018450:Disease Progression; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006689:Hodgkin Disease / Q000188:drug therapy / Q000628:therapy*; D006801:Humans; D021621:Imaging, Three-Dimensional; D007167:Immunotherapy / Q000379:methods; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D000077594:Nivolumab; D049268:Positron-Emission Tomography; D061026:Programmed Cell Death 1 Receptor / Q000378:metabolism; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; D000077594:Nivolumab
references.citation: Blood. 2010 Oct 28;116(17):3268-77
references.pmid: 20628145
references.citation: Clin Cancer Res. 2012 Mar 15;18(6):1611-8
references.pmid: 22271878
references.citation: N Engl J Med. 2015 Jan 22;372(4):311-9
references.pmid: 25482239
references.citation: Blood. 2008 Dec 1;112(12):4371-83
references.pmid: 19029455
references.citation: Blood. 2009 Sep 3;114(10):2149-58
references.pmid: 19597183
references.citation: Clin Cancer Res. 2011 Jul 1;17(13):4232-44
references.pmid: 21540239
references.citation: JAMA Oncol. 2015 Jul;1(4):433-40
references.pmid: 26181250
references.citation: N Engl J Med. 2015 Jul 9;373(2):123-35
references.pmid: 26028407